Skip to main content

Table 1 Demographic and clinical data

From: A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study

  

Total

Affected mutation carriers

Presymptomatic mutation carriers

Non-carriers

p-value

Number of individuals

221

47

98

76

Sex distribution [F/M]

119/102

20/27

58/40

41/35

0.17a

Age [mean ± SD (range)]

50 ± 14 (20–76)

62 ± 9 (38–76)

46 ± 12 (20–74)

47 ± 13 (20–69)

3e-14b

Age at onset [mean ± SD (range)]

 

58 ± 9 (35–73)

  

Mutation [N (%)]

C9orf72

 

27 (57)

41 (42)

  

GRN

 

12 (26)

38 (39)

  

MAPT

 

7 (15)

16 (16)

  

TBK1

 

1 (2)

3 (3)

  

Clinical phenotype [N (%)]

bvFTD

 

32 (68)

   

PPA

 

7 (15)

   

Otherc

 

8 (17)

   
  1. Age measured in years
  2. AMC affected mutation carriers, PMC presymptomatic mutation carriers, NC non-carriers, C9orf72 chromosome 9 open reading frame 72, GRN progranulin, MAPT microtubule associated protein tau, TBK1 TANK-binding kinase 1, bvFTD behavioural variant frontotemporal dementia, PPA primary progressive aphasia, FTD-ALS frontotemporal dementia with amyotrophic lateral sclerosis, PSP progressive supranuclear palsy, D-NOS dementia not otherwise specified
  3. aFisher’s exact test
  4. bANOVA. Tukey’s Honestly Significant Difference (Tukey’s HSD) post-hoc test was performed for pairwise comparisons (AMC vs NC, p = 3e-11; AMC vs PMC, p = 2e-13; PMC vs NC, p = 0.8)
  5. cOther clinical phenotypes included ALS (n = 4), FTD-ALS (n = 1), PSP (n = 2), D-NOS (n = 1)